Evidence map›Paper›PMID 33609308›Full record

ArticleHepatology (Baltimore, Md.)2021

County-Level Variation in Hepatitis C Virus Mortality and Trends in the United States, 2005-2017.

Eric W Hall, Sarah Schillie, Adam S Vaughan, Jeb Jones, Heather Bradley, Ben Lopman, Eli S Rosenberg, Patrick S Sullivan

Abstract readHistorical Article
In one paragraph

Article in Hepatology (Baltimore, Md.), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Hepatitis C Surveillance in the United States: Past, Present, and Future.Public health reports (Washington, D.C. : 1974) · 2025
    Review
  5. Article
  6. Review
  7. Article
  8. Human Riboviruses: A Comprehensive Study.Journal of molecular evolution · 2025
    Review
  9. Disparities in hepatitis C among people aged 12-59 with no history of injection drug use, United States, January 2013-March 2020.Liver international : official journal of the International Association for the Study of the Liver · 2024
    Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors.

Eric W HallDepartment of EpidemiologyRollins School of Public HealthEmory UniversityAtlantaGA.ORCID 0000-0003-0244-7458
Sarah SchillieImmunization Services DivisionCenters for Disease Control and PreventionAtlantaGA.
Adam S VaughanDivision for Heart Disease and Stroke PreventionCenters for Disease Control and PreventionAtlantaGA.
Jeb JonesDepartment of EpidemiologyRollins School of Public HealthEmory UniversityAtlantaGA.
Heather BradleyDepartment of Epidemiology and BiostatisticsSchool of Public HealthGeorgia State UniversityAtlantaGA.
Ben LopmanDepartment of EpidemiologyRollins School of Public HealthEmory UniversityAtlantaGA.
Eli S RosenbergDepartment of Epidemiology and BiostatisticsSchool of Public HealthUniversity at AlbanyAlbanyNY.
Patrick S SullivanDepartment of EpidemiologyRollins School of Public HealthEmory UniversityAtlantaGA.

Funding

Virology and Molecular Biomarkers CoreP30AI050409 · NIAID · EMORY UNIVERSITY · PI Ann M Chahroudi, Colleen F Kelley · 2002 to 2026
$74.0M
NIAID NIH HHS P30 AI050409
6 · The paper itself

Abstract

BACKGROUND AND

aimsSince 2013, the national hepatitis C virus (HCV) death rate has steadily declined, but this decline has not been quantified or described on a local level. APPROACH AND

resultsWe estimated county-level HCV death rates and assessed trends in HCV mortality from 2005 to 2013 and from 2013 to 2017. We used mortality data from the National Vital Statistics System and used a Bayesian multivariate space-time conditional autoregressive model to estimate age-standardized HCV death rates from 2005 through 2017 for 3,115 U.S. counties. Additionally, we estimated county-level, age-standardized rates for persons <40 and 40+ years of age. We used log-linear regression models to estimate the average annual percent change in HCV mortality during periods of interest and compared county-level trends with national trends. Nationally, the age-adjusted HCV death rate peaked in 2013 at 5.20 HCV deaths per 100,000 persons (95% credible interval [CI], 5.12, 5.26) before decreasing to 4.34 per 100,000 persons (95% CI, 4.28, 4.41) in 2017 (average annual percent change = -4.69; 95% CI, -5.01, -4.33). County-level rates revealed heterogeneity in HCV mortality (2017 median rate = 3.6; interdecile range, 2.19, 6.77), with the highest rates being concentrated in the West, Southwest, Appalachia, and northern Florida. Between 2013 and 2017, HCV mortality decreased in 80.0% (n = 2,274) of all U.S. counties with a reliable trend estimate, with 25.8% (n = 803) of all counties experiencing a decrease larger than the national decline.

conclusionsAlthough many counties have experienced a shift in HCV mortality trends since 2013, the magnitude and composition of that shift have varied by place. These data provide a better understanding of geographic differences in HCV mortality and can be used by local jurisdictions to evaluate HCV mortality in their areas relative to surrounding areas and the nation.

Indexed as

AdolescentAdultAge DistributionChildChild, PreschoolFemaleGeographyHepatitis CHistory, 21st CenturyHumansInfantInfant, NewbornMaleMiddle AgedMortalitySpatio-Temporal Analysis

Identifiers

PMID33609308
PMCPMC8456961

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.